Research and Development, Clinical and Experimental Research are Core Activities at Circularity

Circularity's core activity is conducting cutting-edge clinical trials.

We investigate the myriad benefits, mechanisms of actions, physiological and molecular functions of the body's natural microcirculatory system based on the exchange of non-toxic medical gases (gasotransmitters) via transdermal delivery.

We are working with leading institutions, researchers, and health practitioners in the United States and many other countries to establish further evidence for a wide variety of therapeutic modalities, scientific, and clinical outcomes.

Source: Penn State University, Philadelphia, PA U.S.A. | | Valley Presbyterian Hospital, Los Angeles, CA U.S.A.

We are constantly conducting, collaborating on, and sponsoring clinical trials for multiple conditions at the same time. For example, spider and varicose veins, severe acne breakouts, fibromyalgia, chronic headaches, wound healing related to diabetes and cardiovascular complications, pain management related to neuropathy and other chronic conditions, mental health complications and a variety of cancer types including multiple myloma.

Our company has embarked on a licensing program to develop new methods to deliver existing and new pharmaceutical APIs, supplements, vitamins, creams, and other beneficial substances via transdermal means unique only to Circularity's proprietary, patent-pending platform.

We are constantly seeking opportunities to sponsor and collaborate on research activities, please contact us if you would like to participate in Circularity's Center of Excellence (COE) program and set up clinical trials.

Impaired tissue perfusion denies oxygen and blood flow where it is needed most, preventing the body from delivering its natural pain relief and slowing the healing process. Few patients, however, suffer as much from poor circulation as those with Type 1 and Type 2 diabetes do. Poor circulation in these patients can result in neuropathy pain, ulcers, and even necrosis. Restrictions in this form of circulation impede the flow of antibodies, white blood cells and platelets, and rob the body of oxygen.

Researchers are continuously seeking out therapies that reduce these symptoms, and recent clinical research has revealed a promising, affordable possibility. This advanced transdermal solution works by bolstering the body’s natural healing foundation: the autonomic nervous system and microcirculation.

In a clinical trial, D'OXYVA achieved the following three groundbreaking results:

  • It improved microcirculation (Skin Perfusion Pressure) in a statistically significant manner in each individual by 15-100%.

  • The improvement in blood flow peaked uniformly within hours after a single 5-minute delivery on the thumb, and subsequently lasted for several hours.

  • All enrolled subjects responded positively without adverse events after being monitored for a year after the study.

In various studies with D'OXYVA, victims of neuropathy, peripheral vascular complications, bodily injury, surgical complications, and other forms of pain reported significant reduction in symptoms and pain in 8 out of 10 cases. Even more impressively, 9 out of 10 users reported significant long term health benefits, after only 6 to 8 weeks of use.

Circularity has been assembling a Scientific Advisory Board that includes domestic and international medical-thought leaders in the field of endocrinology, diabetic pain relief, wound healing, microvascular physiology, neurobiology, oncology, amputation prevention, cardiovascular and exercise physiology. These clinical and academic physicians, with a combined total of over 1,000 publications, are tasked with investigating the D'OXYVA delivery system, and ascertaining the potential benefits of combating destructive symptoms of diabetes and other health complications through boosting microcirculation.

The D'OXYVA product is considered an “investigational device” when used for medical purposes in clinical tests and is deemed to have an “investigational device exemption” (“IDE”) in place because it has been the subject of an IRB-approved Non-Significant Risk (NSR) device study.